Helix BioPharma Corp. (HBPCF)
- Previous Close
0.1377 - Open
0.1378 - Bid --
- Ask --
- Day's Range
0.1377 - 0.1377 - 52 Week Range
0.1377 - 0.1500 - Volume
287 - Avg. Volume
498 - Market Cap (intraday)
32.748M - Beta (5Y Monthly) -0.74
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Jun 12, 2024 - Jun 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
www.helixbiopharma.comRecent News: HBPCF
Performance Overview: HBPCF
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HBPCF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HBPCF
Valuation Measures
Market Cap
35.27M
Enterprise Value
34.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
69.40
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-5.87
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-111.88%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.94M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
1.64M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.41M
Company Insights: HBPCF
HBPCF does not have Company Insights